NovoCure (NVCR) Stock Price, News & Analysis

Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key Stats

• Today's Range: $11.07 to $11.55
• 50-Day Range: $10.97 to $19.40
• 52-Week Range: $10.91 to $34.13
• Volume: 2.06 million shs
• Average Volume: 1.70 million shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.79
• Consensus Rating: Moderate Buy

NovoCure Stock Analysis - MarketRank™

NovoCure scored higher than 88% of companies evaluated by MarketBeat, and ranked 118th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

NovoCure has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovoCure is -7.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovoCure is -7.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovoCure has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.99% of the float of NovoCure has been sold short.

Short Interest Ratio / Days to Cover

NovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovoCure does not currently pay a dividend.

Dividend Growth

NovoCure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.15

Percentage of Shares Shorted

4.99% of the float of NovoCure has been sold short.

Short Interest Ratio / Days to Cover

NovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.38

News Sentiment

NovoCure has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for NovoCure this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 5.52% of the stock of NovoCure is held by insiders.

Percentage Held by Institutions

84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVCR Stock Analysis - Frequently Asked Questions

How have NVCR shares performed this year?

NovoCure's stock was trading at $29.80 at the start of the year. Since then, NVCR stock has decreased by 62.0% and is now trading at $11.32.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its earnings results on Thursday, July, 24th. The medical equipment provider reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. NovoCure's quarterly revenue was up 5.6% compared to the same quarter last year.
Read the conference call transcript.

Who are NovoCure's major shareholders?

NovoCure's top institutional shareholders include Taylor Frigon Capital Management LLC (0.11%), Teacher Retirement System of Texas (0.05%), Jennison Associates LLC (0.03%) and KLP Kapitalforvaltning AS (0.02%). Insiders that own company stock include William F Doyle, Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Ely Benaim, Asaf Danziger and Mukund Paravasthu.
View institutional ownership trends.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

• Last Earnings: 7/24/2025
• Today: 8/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NVCR
• CIK: 1645113
• Web: www.novocure.com
• Phone: 441534756700
• Fax: N/A
• Employees: 1,488
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NovoCure: $28.79
• High Price Target: $38.00
• Low Price Target: $14.50
• Potential Upside/Downside: +154.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$168.63 million
• Net Margins: -27.13%
• Pretax Margin: -22.54%
• Return on Equity: -47.74%
• Return on Assets: -13.79%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.45
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $630.16 million
• Price / Sales: 2.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.13 per share
• Price / Book: 3.62

Miscellaneous

• Outstanding Shares: 111,799,000
• Free Float: 105,628,000
• Market Cap: $1.27 billion
• Optionable: Optionable
• Beta: 0.72